Bafna Pharmaceuticals share news and announcements
NSE: BAFNAPHBSE: 532989Pharmaceuticals & BiotechnologySmall Cap
Last close ₹442.95down ₹9.00 (1.99%)BSE ₹449.85
Share price at the NSE close on 23 Oct 2026. Previous close ₹451.95.
52-week range of traded prices to 23 Oct 2026
₹94.77Low, 16 Mar 2026₹479.95High, 21 Oct 2026
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹1,048 Cr2,105th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 11 Aug 2026
- 134.6
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 29 May 2026
- 10.9
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 11 Aug 2026
- 8.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 11 Aug 2026
- 4.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.39
- Volume, NSEVolume. Shares traded on the last trading day.
- 1,422
Bafna Pharmaceuticals share news and announcements
637 announcements, routine notices left out, newest first. Page 5 of 13.
Feb 2020
13 Feb · Board meeting
Dec 2019
Nov 2019
13 Nov · Board meeting
Aug 2019
21 Aug · Suspension of trading in equity shares
Members of the Exchange are hereby informed that the trading in Equity Shares of Bafna Pharmaceuticals Limited shall be suspended w.e.f. August 26, 2019 (i.e. closing hours of trading on August 23, 2019) on account of Reduction of Share Capital.14 Aug · Legal
Exchange has sought clarification from Bafna Pharmaceuticals Limited for the quarter ended 30-Jun-2019 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.10 Aug · Board meeting
Jul 2019
16 Jul
File name: “updatetostockexchangedated16thjuly2019”
Jun 2019
24 Jun · Related Party Transactions
May 2019
29 May · Legal
Exchange has sought clarification from Bafna Pharmaceuticals Limited with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results not signed by authorized signatory/ies The response of the Company is awaited.27 May · Board meeting
Apr 2019
3 Apr
File name: “Intimationtostockexchange03rdApril2019”
Mar 2019
11 Mar · Corporate Insolvency Resolution Process
Feb 2019
13 Feb · Corporate Insolvency Resolution Process
8 Feb · Board meeting
5 Feb · Corporate Insolvency Resolution Process
Jan 2019
Nov 2018
26 Nov · Corporate Insolvency Resolution Process
Sep 2018
6 Sep · Board meeting
Aug 2018
13 Aug · Board meeting
Jul 2018
20 Jul · Legal
Exchange has sought clarification from Bafna Pharmaceuticals Limited with respect to announcement dated 18-Jul-2018, regarding " Bafna Pharmaceuticals Limited has informed the Exchange regarding 'Disclosure pursuant to Regulation 30 of SEBI ( Listing Obligations and Disclosure Requirements) Regulations, 2015.'.". On basis of above the Company is required to clarify following: 1. Any other material information not involving commercial secrets 2. Salient features, not involving commercial secrets, of the resolution plan approved by the Tribunal, in such form as may be specified 3. Approval of resolution plan by the Tribunal or rejection, if applicable 4. Filing of resolution plan with the Tribunal 5. Number of resolution plan with the Tribunal 6. Brief particulars of invitation of resolution plans under section 25(2)(h) of Insolvency Code in the Form specified under regulation 36A(5) of IBBI (Insolvency Resolution Process for Corporate Persons) Regulations,2016 7. Prior or post-facto intimation of the meetings of Committee of Creditors 8. Appointment/Replacement of the Resolutions Professional 9. List of creditors as required to be displayed by the corporate debtor under regulation 13(2)(c) of the IBBI (Insolvency Resolution process for Corporate Persons ) Regulations.2016 10. Public announcement made pursuant to order passed by the Tribunal under section 13 of Insolvency Code 11. Admission of application by the Tribunal, along with amount of default or rejection or withdrawal, as applicable 12. Filing of application by financial creditors for initiation of CIRP against the corporate debtor, also specifying the amount of default 13. Filing of application by financial creditors for initiation of CIRP also specifying the amount of default The response of the Company is awaited.